
City Therapeutics Secures $99.5M Series B for RNAi - Ventureburn
City Therapeutics is a biotechnology company focused on developing RNA interference (RNAi) therapies. Their innovative platform utilizes engineered RNAi trigger molecules to deliver treatments beyond the liver, targeting diseases such as thromboembolic disorders and Stargardt disease. The recent $99.5 million funding will support the advancement of their clinical pipeline.
City Therapeutics Secures $99.5M Series B for RNAi Ventureburn

| Jun 29, 2026 | Omen AI | $31.0M | — | United States |
| Jun 29, 2026 | Techdollar | $3.0M | Pre-seed | United States |
| Jun 29, 2026 | Su | $3.0M | — | United States |
| Jun 29, 2026 | Warp | $60.0M | Series B | United States |